Skip to content

Improvement and Application of New Closed Drainage Device

Improvement and Clinical Application of a New Minimally Invasive Closed Thoracic Drainage System

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04143360
Acronym
IAAONCDD
Enrollment
100
Registered
2019-10-29
Start date
2020-04-30
Completion date
2021-09-30
Last updated
2020-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hydrothorax, Pneumothorax

Brief summary

According to the problems of traditional closed thoracic drainage in clinical work, this study aims to further improve and improve the new closed thoracic drainage system by changing the material of drainage tube, increasing the regulating valve of external fixator and increasing the gas flow monitoring kit for special patients, so as to expand its clinical application scope and formulate its operation. Standardize. At the same time, through a randomized controlled study, the simplicity, effectiveness and safety of the new minimally invasive thoracic closed drainage system developed by the research group were deeply studied.

Detailed description

The traditional closed thoracic drainage method has complex operation and high technical requirements. It has obvious pain during and after operation. Operational complications such as tissue organs, intercostal vessels and nerve injury may occur during the operation. Accidents may also occur after catheterization, including leakage around thoracic drainage tube, thoracic drainage tube prolapse, subcutaneous emphysema and accumulation. Liquid; To solve these problems, we have invented minimally invasive thoracic closed drainage system through a number of patent designs, including: thoracic closed drainage tube implantation expansion forceps, double-chamber thoracic drainage device with side balloon, guide wire, puncture needle, various types of dilators, chest tube fixation devices, etc. The system has the characteristics of minimally invasive puncture and implantation of drainage tube, safe, fast operation, no need of suture and fixation, good position of drainage tube after implantation, less pain for patients, and closing incision in the medial part of patients, avoiding leakage and subcutaneous emphysema and hydrops.

Interventions

DEVICENew Closed Drainage Device

For the first group, a new closed drainage device was adopted.

DEVICETraditional closed drainage device

For group 2, conventional closed drainage device was used.

Sponsors

Yongxin Zhou
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

The selection criteria were as follows: * age 18-70 years, gender is not limited; * subjects clearly understand the purpose of the study, are willing and able to comply with the requirements to complete the study and sign the informed consent; * 18 Kg/m2 \< BMI \< 25 Kg/m2; * patients who need thoracic closed drainage for exhaust and drainage because of pneumothorax volume \> 30%; * subjects did not have serious chest wall deformities.

Exclusion criteria

* Patients at high risk of bleeding, including patients with congenital hemophilia, thrombocytopenia (PLT \< 50 \*109/L), platelet dysfunction (such as idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, congenital platelet dysfunction); * Cardiopulmonary function is poor, which is not suitable for the participants. * Patients with other infectious diseases (inflammation, tuberculosis) or empyema in the thoracic cavity; * Infection of skin around puncture and drainage; * Participated in other clinical trials within 30 days; * Other reasons why the researchers think it is inappropriate to participate in the experiment.

Design outcomes

Primary

MeasureTime frameDescription
Total drainage timeup to 24 weeksEfficiency of treatment
Pulmonary reexpansion ratioup to 24 weeksPulmonary reexpansion ratio

Secondary

MeasureTime frameDescription
VAS pain score during and after operationup to 24 weeks0 points means no pain; 1 points - 3 points means mild pain that patients can tolerate; 4 points - 6 points means pain affect sleep, but patients can tolerate;7 points - 10 points: means patients have gradually strong pain, which have affected appetite and sleep.

Other

MeasureTime frameDescription
Incidence of related accidents after catheterizationup to 24 weeksIncidence rate of peri-drainage tube exudation, drainage tube falling off, drainage tube obstruction and subcutaneous emphysema
Operation time of thoracentesisup to 24 hoursOperation time of thoracentesis
infection of the woundup to 24 weeksinfection of the wound
The size of the woundup to 24 weeksThe size of the wound
Percentage of lung recruitment on day 1 and 3up to 24 weeksPercentage of lung recruitment
Operational-related complicationsup to 24 weeksIncidence of loss of thoracic wall nerves, intercostal vessels and thoracic and abdominal organs

Contacts

Primary ContactWenli Wang, Master's degree
Anderson840913@163.com13761295864
Backup ContactYongxin zhou
zhou6302@tongji.edu.cn13681666828

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026